Clinical trial
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated…
NCT00088166 · Celtic Pharma Development Services, Industry · Completed
Key facts
| NCT number | NCT00088166 |
|---|---|
| Title | XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors |
| Official title | A Phase III Randomized, Double-Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Malignant Brain Tumor Who Require Chronic Administration of High-Dose Dexamethasone |
| Lead sponsor | Celtic Pharma Development Services, Industry |
| Collaborators | Neurobiological Technologies Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Brain Edema, Brain Tumor |
| Intervention type | Drug |
| Interventions | hCRF, placebo hCRF |
| Enrollment | 200 |
| Start date | May 1, 2004 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Jul 22, 2004 |
| Last update posted | Aug 13, 2014 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: